Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3091 to 3105 of 8314 results

  1. Colorectal cancer . Patient decision aid on Lynch syndrome: should I take aspirin to reduce my chance of getting bowel cancer?

    1 Lynch syndrome: should I take aspirin to reduce my chance of getting bowel cancer? Patient decision aid How likely am I to benefit? If you take...

  2. Hypertension in adults. Patient decision aid on how do I control my blood pressure? Lifestyle options and choice of medicines

    1 How do I control my blood pressure? Lifestyle options and choice of medicines Patient decision aid c NICE 2019. All rights reserved. Subject to...

  3. Accessing NHS care and treatment recommended by NICE (ECD4)

    This document contains advice to help you access treatments and care that NICE has recommended

  4. Healthy start vitamins: special report on cost effectiveness (ECD5)

    This document describes a special report on the cost effectiveness of moving the Healthy Start vitamin programme from the current targeted offering to a universal offering

  5. Accessibility changes: notes for developers (ECD6)

    This document summarises the most common accessibility changes NICE is making in guidelines, and why

  6. Evidence standards framework for digital health technologies (ECD7)

    This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England

  7. Standards framework for shared-decision-making support tools, including patient decision aids (ECD8)

    This document describes the framework for setting out a series of standards to support people using patient decision aids (PDAs) in assessing the usefulness and quality of a PDA. It will also be useful to those developing PDAs in enabling them to undertake a self-assessment of the quality of their tools and processes

  8. NICE real-world evidence framework (ECD9)

    This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  9. Further information about MTAC registration and meetings

    More detail about Medical Technologies Advisory Committee (MTAC) registration, meeting arrangements and types of attendee.

  10. Quality standards advisory committee

    Membership details, terms of reference and future meeting dates for our quality standards advisory committee.

  11. Further information about DAC registration and meetings

    More detail about Diagnostics Advisory Committee (DAC) registration, meeting arrangements and types of attendee.

  12. Further information about IPAC registration and meetings

    More detail about Interventional Procedures Advisory Committee (IPAC) registration, meeting arrangements and types of attendee.

  13. Weight management: advice for people living with overweight (18 to 39 years) (IND319)

    This indicator covers the percentage of patients aged 18 to 39 years with a BMI of 23 kg/m2 to 27.4 kg/m2 (or 25 kg/m2 to 29.9 kg/m2 if ethnicity is recorded as White) in the preceding 12 months who have been given weight management advice within 90 days of the BMI being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  14. Infections: scoring tools for sore throat (IND323)

    This indicator covers the percentage of diagnoses of sore throat in the preceding 12 months with a recorded FeverPain or Centor score. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  15. Kidney conditions: CKD and SGLT2 inhibitors (IND322)

    This indicator covers the percentage of patients on the CKD register and currently treated with an angiotensin receptor blocker (ARB) or an ACE inhibitor (unless these are contraindicated) who are also treated with an SGLT-2 inhibitor if they have: no type 2 diabetes and an eGFR 20 ml/min/1.73 m2 to 44 ml/min/1.73 m2, or no type 2 diabetes and an eGFR 45 ml/min/1.73 m2 to 59 ml/min/1.73 m2 and a urine albumin-to-creatinine ratio (ACR) of 22.6 mg/mmol or more, or type 2 diabetes and a urine ACR 3 mg/mmol or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes